Short answer
Xenon Pharmaceuticals Inc. (XENE) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$91M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$91M
- −44.8% YoY · −7.3% QoQ
- EPS (diluted)
- −$1.15
- −42.0% YoY · −7.5% QoQ
Source: XBRL data from the Xenon Pharmaceuticals Inc. (XENE) Q3 2025 10-Q on SEC EDGAR. USD.
Xenon Pharmaceuticals Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factors disclosed; risks consistent with prior 10-K
- Most materially updated: net losses increased to $240.6M for nine months ended Sept 30, 2025, from $168.6M in same period 2024, driven by expanded R&D and G&A expenses
- Legal/compliance risk: potential liability from employee or partner misconduct, including FDA/EMA violations, data privacy breaches, healthcare fraud, could lead to fines, reputational harm, or exclusion from federal programs
- Operational/market risk: intense competition from larger pharmaceutical firms with greater resources, risking market share loss for future epilepsy, MDD, and bipolar disorder products
- Financial risk: ongoing need to raise capital amid significant losses and uncertainty around timing and costs of FDA approvals; cash runway sufficient for 12 months but future funding not assured
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xenon Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.